Annex 1.


Annex 2.SYSTEMIC THERAPY FOR ADVANCED OR METASTATIC DISEASE
- mFOLFOX 6
Oxaliplatin 85 mg/m2 IV day 1z Leucovorin 400 mg/m2 IV day 1aa
5-FU 400 mg/m2 IV bolus on day 1, followed by 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46–48 hours) IV continuous infusion
Repeat every 2 weeks
- mFOLFOX 7
Oxaliplatin 85 mg/m2 IV day 1z Leucovorin 400 mg/m2 IV day 1aa
5-FU 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46–48 hours) IV continuous infusion
Repeat every 2 weeks
- FOLFOX + bevacizumab
Bevacizumab mg/kg IV, day 1 Repeat every 2 weeks
- FOLFOX + panitumumab (KRAS/NRAS/BRAF WT)
Panitumumab 6 mg/kg IV over 60 minutes, day 1 ---Repeat every 2 weeks
- FOLFOX + cetuximab (KRAS/NRAS/BRAF WT)
Cetuximab 400 mg/m2 IV over 2 hours first infusion, followed by 250 mg/m2 IV over 60 minutes weekly or Cetuximab 500 mg/m2 IV over 2 hours, day 1, every 2 weeks (preferred for every 2 weeks)
- CAPEOX8
Oxaliplatin 130 mg/m2 IV day 1z
Capecitabine 1000cc mg/m2 twice daily PO for 14 days
Repeat every 3 weeks
- CAPEOX + bevacizumab
Oxaliplatin 130 mg/m2 IV day 1z
Capecitabine 1000cc mg/m2 PO twice daily for 14 days
Bevacizumab 7.5 mg/kg IV day 1 Repeat every 3 weeks
CAPEOX + cetuximab (KRAS/NRAS/BRAF WT)
Cetuximab 400 mg/m2 IV over 2 hours first infusion, followed by 250 mg/m2 IV over 60 minutes weekly or Cetuximab 500 mg/m2 IV over 2 hours, day 1, every 2 weeks (preferred for every 2 weeks)
CAPEOX + panitumumab9-11 (KRAS/NRAS/BRAF WT)
Panitumumab 6 mg/kg IV over 60 minutes, day 1 Repeat every 2 weeks
FOLFIRI
Irinotecan 180 mg/m2 IV over 30–90 minutes, day 1
Leucovorinaa 400 mg/m2 IV infusion to match duration of irinotecan infusion,
day 1
5-FU 400 mg/m2 IV bolus day 1, followed by 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46–48 hours) continuous infusion
Repeat every 2 weeks
- FOLFIRI + bevacizumab
Bevacizumab 5 mg/kg IV, day 1 Repeat every 2 weeks
- FOLFIRI + cetuximab (KRAS/NRAS/BRAF WT)
Cetuximab 400 mg/m2 IV over 2 hours first infusion, followed by 250 mg/m2 IV over 60 minutes weekly or Cetuximab 500 mg/m2 IV over 2 hours, day 1, every 2 weeks (preferred
for every 2 weeks)
- FOLFIRI + panitumumab (KRAS/NRAS/BRAF WT)
Panitumumab 6 mg/kg IV over 60 minutes, day 1 Repeat every 2 weeks
- FOLFIRINOX20
Oxaliplatin 85 mg/m² IV on day 1,z leucovorin 400 mg/m² IV over 2 hours on day 1, irinotecan 165–180 mg/m² IV over 30–90 minutes on day 1, 5-FU 400 mg/m² IV push day 1, 5-FU 1200 mg/m²/day x 2 days (total 2400 mg/m² over 46 hours) continuous infusion.
Repeat every 2 weeks
- Modified FOLFIRINOX
Oxaliplatin 85 mg/m² IV on day 1,z leucovorin 400 mg/m² IV over 2 hours on day 1, irinotecan 150 mg/m² IV over 30–90 minutes on day 1, 5-FU 1200 mg/m²/day x 2 days (total 2400 mg/m² over 46 hours) continuous infusion. Repeat every 2 weeks
- FOLFIRINOX or mFOLFIRINOX + bevacizumab
Bevacizumab 5 mg/kg IV, day 1
Repeat every 2 weeks
- IROX
Oxaliplatin 85 mg/m2 IV
followed by irinotecan 200 mg/m2 over 30–90 minutes every 3 weeks
- IROX + bevacizumab
Bevacizumab 7.5 mg/kg IV on day 1 Repeat every 3 weeks
- Bolus or infusional 5-FU/leucovorin Roswell Park regimen
Leucovorin 500 mg/m2 IV over 2 hours, days 1, 8, 15, 22, 29, and 36
5-FU 500 mg/m2 IV bolus 1 hour after start of leucovorin,
days 1, 8, 15, 22, 29, and 36
Repeat every 8 weeks
- Simplified biweekly infusional 5-FU/leucovorin (sLV5FU2)
Leucovorinaa 400 mg/m2 IV over 2 hours on day 1,
followed by 5-FU bolus 400 mg/m2 followed by 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46–48 hours) continuous infusion Repeat every 2 weeks
Weekly Leucovorin 20 mg/m2 IV over 2 hours on day 1, 5-FU 500 mg/ m2 IV bolus injection 1 hour after the start of leucovorin. Repeat weekly27
or
5-FU 2600 mg/m2 by 24-hour infusion plus leucovorin 500 mg/m2 Repeat every week
- Bolus or infusional 5-FU + bevacizumab
Bevacizumab 5 mg/kg IV on day 1
Repeat every 2 weeks
- Capecitabine
Capecitabine 850–1250 mg/m2 PO twice daily for 14 days Repeat every 3 weeks
- Capecitabine + bevacizumab
Bevacizumab 7.5 mg/kg IV, day 1 Repeat every 3 weeks
l Irinotecan
Irinotecan 125 mg/m2 IV over 30–90 minutes, days 1 and 8 Repeat every 3 weeks
or Irinotecan 180 mg/m2 IV over 30–90 minutes, day 1 Repeat every 2 weeks
or Irinotecan 300–350 mg/m2 IV over 30–90 minutes, day 1 Repeat every 3 weeks
- Irinotecan + cetuximab (KRAS/NRAS/BRAF WT)
Cetuximab 400 mg/m2 first infusion, followed by 250 mg/m2 IV weekly32
or Cetuximab 500 mg/m2 IV over 2 hours, day 1, every 2 weeks16
(preferred for every 2 weeks)
- Irinotecan + panitumumab17,33 (KRAS/NRAS/BRAF WT)
Panitumumab 6 mg/kg IV over 60 minutes every 2 weeks
- Irinotecan + bevacizumab34,bb Irinotecan 180 mg/m2 IV, day 1
Bevacizumab 5 mg/kg IV, day 1 Repeat every 2 weeks
or
Irinotecan 300–350 mg/m2 IV, day 1
Bevacizumab 7.5 mg/kg IV, day 1 Repeat every 3 weeks
Cetuximab (KRAS/NRAS/BRAF WT)
Cetuximab 400 mg/m2 first infusion, followed by 250 mg/m2 IV weekly32
or Cetuximab 500 mg/m2 IV over 2 hours, day 1, every 2 weeks16
(preferred for every 2 weeks)
Panitumumab35 (KRAS/NRAS/BRAF WT)
Panitumumab 6 mg/kg IV over 60 minutes every 2 weeks
- Trastuzumab + pertuzumab
(HER2-amplified and RAS and BRAF WT)
Trastuzumab 8 mg/kg IV loading dose on day 1 of cycle 1, followed by 6 mg/kg IV every 21 days
Pertuzumab 840 mg IV loading dose on day 1 of cycle 1, followed by 420 mg IV every 21 days
- Trastuzumab + lapatinib
(HER2-amplified and RAS and BRAF WT)
Trastuzumab 4 mg/kg IV loading dose on day 1 of cycle 1, followed by 2 mg/kg IV weekly
Lapatinib 1000 mg PO daily